Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 10/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 5/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12508573 | 0.91 | ALDH1A1 (0.49) | FAAHALDH1A1NAMPTCYP2D6 | |
| SCHEMBL12509406 | 0.89 | ALDH1A1 (0.48) | FAAHALDH1A1HTR2AHTR2CNAMPT | |
| SCHEMBL12509399 | 0.88 | MGLL (0.51) | FAAHALDH1A1HTR2AHTR2C | |
| SCHEMBL12509070 | 0.88 | MGLL (0.51) | FAAHALDH1A1HTR2AHTR2C | |
| SCHEMBL12508869 | 0.88 | MGLL (0.51) | FAAHALDH1A1HTR2AHTR2C | |
| SCHEMBL12509253 | 0.87 | NAMPT (0.50) | FAAHALDH1A1HTR2AHTR2CNAMPT | |
| SCHEMBL12508860 | 0.87 | NAMPT (0.50) | FAAHALDH1A1HTR2AHTR2CNAMPT | |
| SCHEMBL12508867 | 0.87 | NAMPT (0.50) | FAAHALDH1A1HTR2AHTR2CNAMPT | |
| SCHEMBL12509403 | 0.86 | PDE4A (0.47) | FAAHALDH1A1HTR2AHTR2CNAMPT | |
| SCHEMBL12509036 | 0.86 | ALDH1A1 (0.50) | FAAHALDH1A1HTR2AHTR2CNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | FAAH 1/4885ALDH1A1 259/4885HTR2A 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.